Objective: To show the initial (first-year) experience with 68Ga-PSMA PET/CT at a clinic in Brazil. Materials and Methods: Over a one-year period, 96 examinations with 68Ga-PSMA PET/CT (85 related to prostate cancer and 11 related to kidney cancer) were performed in 90 patients. Results: In the prostate and kidney cancer patients alike, the main clinical indication for 68Ga-PSMA PET/CT was suspicion of recurrence during follow-up (in 65.8% and 63.0% of the cases, respectively). Among the prostate cancer patients, 38.5% of those with a prostate specific antigen (PSA) < 0.5 ng/mL tested positive for recurrence on 68Ga-PSMA PET/CT, compared with 71.0% of those with a PSA of 0.5–0.99, 85.7% of those with a PSA of 1.0–1.99, and 92.6% of those with a PSA > 1.99. Conclusion: Although 68Ga-PSMA PET/CT is a technique that has only recently been applied in clinical settings, despite its high cost, 68Ga-PSMA PET/CT shows great promise as a tool in the clinical management of patients with kidney and prostate cancer, especially in those with prostate cancer whose PSA levels are elevated even after treatment.
CITATION STYLE
Prado Júnior, L. M., Marino, F. M., Barra, R., Do Prado, L. F. M., & Sobrinho, A. B. (2018). One-year experience with 68Ga-PSMA PET/CT: Applications and results in biochemical recurrence of prostate cancer. Radiologia Brasileira, 51(3), 151–155. https://doi.org/10.1590/0100-3984.2017.0008
Mendeley helps you to discover research relevant for your work.